Table 1.
Clinical features of the participants who contributed plasma
| Characteristics | RA | OA | HC |
|---|---|---|---|
| Number of participants | 30 | 30 | 30 |
| Sex, male/female | 8/22 | 7/23 | 13/17 |
| Age, mean (range) | 60.1 (22 to 77) | 75.1 (65 to 89) | 46.5 (32 to 62) |
| Disease duration (y), mean (range) | 10.4 (0.3 to 32) | NA | NA |
| Positive anti-CCP antibody, n (%) | 10 (90.9%)† | NA | NA |
| ESR (mm), mean (range) | 37.2 (4 to 116) | NA | NA |
| CRP (mg/dl), mean (range) | 2.1 (0 to 9.6) | NA | NA |
| MMP3 (ng/ml), mean (range) | 290.1 (32.4 to 800) | NA | NA |
| DAS28, mean (range) | 4.4 (1.7 to 7.1) | NA | NA |
| SJC, mean (range) | 4.3 (0 to 13) | NA | NA |
| TJC, mean (range) | 4.5 (0 to 27) | NA | NA |
| VAS | 42.3 (0 to 95) | NA | NA |
| Steinbrocker Stage, n | I: 4, II: 3, III: 6, IV: 17 | NA | NA |
| Steinbrocker Class, n | I: 1, II: 24, III: 5, IV: 0 | NA | NA |
| Kellgren/Lawrence grade, n | NA | I: 0, II: 0, III: 9, IV: 21 | NA |
| Medication, n (%) | |||
| Prednisolone | 21 (70%) | NA | NA |
| Methotrexate | 18 (60%) | NA | NA |
| Infliximab | 8 (27%) | NA | NA |
| Eternercept | 2 (6.7%) | NA | NA |
| Tocilizumab | 2 (6.7%) | NA | NA |
| Tacrolimus | 2 (6.7%) | NA | NA |
| Salazosulfapyridine | 6 (20%) | NA | NA |
| Bucillamine | 5 (17%) | NA | NA |
| Mizoribine | 0 (0%) | NA | NA |
| Gold | 1 (3.3%) | NA | NA |
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, 28-joint Disease Activity Score; ESR, erythrocyte sedimentaition ratio; HC, healthy control; MMP-3, metalloproteinase-3; NA, not applicable; OA, osteoarthritis; RA, rheumatoid arthritis; SJC, swollen joint count; TJC, tender joint count; VAS, visual analogue scale of general health;
† anti-CCP antibodies of 10 patients were positive among 11 patients examined.